The CMS 340B Drug Cost Survey Is a Wrap. So, What Happens Now?

Last week Friday, May 15, was the deadline for hospitals to respond to the Centers for Medicare & Medicaid Services’ (CMS) 340B drug acquisition cost survey. Many 340B hospital senior executives and pharmacy directors probably are asking themselves, “What happens next?”

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content